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Background and purpose: Genistein aglycone positively affects bone loss in postmenopausal women, but bone quality data
are still lacking. To clarify this, we investigated the effects of genistein compared with alendronate, raloxifene and oestradiol in
an animal model of established osteoporosis.
Experimental approach: Six months after ovariectomy, 96 ovariectomized (OVX) rats were divided into 8 equal groups,
randomized to treatments (genistein aglycone (1 and 10mgkg
 1 s.c.); alendronate (0.003 and 0.03mgkg
 1 s.c.); raloxifene
hydrochloride (0.05 and 0.5mgkg
 1 s.c.); 17-a-ethinyl oestradiol (0.003 and 0.03mgkg
 1 s.c.)) for 12 weeks. Untreated OVX
(n¼12) and sham OVX (n¼12) were used as controls. At the beginning and end of treatment, bone mineral density (BMD)
and bone mineral content (BMC) were assessed. At the end of the experiment, calcium, phosphorus, bone-alkaline
phosphatase (b-ALP), collagen C-telopeptide (CTX), osteoprotegerin (OPG) and soluble receptor activator of nuclear factor-kB
ligand (sRANKL) were assayed. Femurs were removed and tested for breaking strength and histology.
Key results: Genistein (10mgkg
 1) showed a greater increase in both BMD (Po0.0001 vs OVX) and BMC than all the other
treatments. Moreover, genistein significantly increased breaking strength, bone quality, b-ALP (Po0.0001 vs OVX) and OPG,
and reduced CTX and sRANKL compared with the other treatments at all dose levels.
Conclusions and implications: The results strongly suggest that the genistein aglycone might be a new therapy for the
management of postmenopausal osteoporosis in humans.
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Abbreviations: b-ALP, bone-alkaline phosphatase; BMC, bone mineral content; BMD, bone mineral density; CTX, collagen
C-telopeptide; ER, oestrogen receptor; OPG, osteoprotegerin; OVX, ovariectomized; sRANKL, soluble receptor
activator of nuclear factor-kB ligand
Introduction
Osteoporosis is a systemic disease, characterized by reduced
bone mass and structural deterioration of bone tissue. It is
considered a public health issue threatening a large part of
the population above 50 years of age (Hohenhaus et al.,
2007; Levine, 2007). Often presenting as a silent disease, it
generally occurs asymptomatically and, consequently, the
afflicted individuals will only be diagnosed after the
occurrence of fractures. Overall, the disease increases
significantly the risk of fractures and requires suitable
medical treatment (Barlow, 2007).
Currently available treatments for postmenopausal osteo-
porosis include hormone replacement therapy, bisphospho-
nates, calcitonin, strontium ranelate, teriparatid and
selective oestrogen receptor modulators (SERMs), such as
raloxifene. Several experimental studies compared the effects
of currently used therapies for osteoporosis in ovariecto-
mized (OVX) animals (Frolik et al., 1996; Sato et al., 1996;
Bourrin et al., 2002; Helvering et al., 2005), but the results
were variable and different doses were used. Moreover,
BJPOpen  
Received 13 March 2008; revised 10 June 2008; accepted 1 July 2008;
published online 11 August 2008
Correspondence: Professor F Squadrito, Section of Pharmacology,
Department of Clinical and Experimental Medicine and Pharmacology,
University of Messina, Torre Biologica, 5th floor, c/o AOU Policlinico G
Martino, Via C Valeria Gazzi, 98125 Messina, Italy.
E-mail: Francesco.Squadrito@unime.it
British Journal of Pharmacology (2008) 155, 896–905
& 2008 Macmillan Publishers Limited All rights reserved 0007–1188/08 $32.00
www.brjpharmacol.orgclinical practice has found that women undergoing treat-
ment for osteoporosis require long-term dosing regimens
that offer no symptomatic relief and may cause side effects.
As with other chronic diseases, continuance and compliance
with therapy are poor.
Hormone replacement therapy is commonly used to treat
postmenopausal bone loss. Even if it is effective in reducing
menopausal symptoms (Castelo-Branco et al., 1999; Writing
Group for the Women’s Health Initiative Investigators, 2002;
Ahlborg et al., 2004), it is associated with a higher risk for
breast, endometrial and in elevated levels of ovarian cancer
as well as cardiovascular disease manifested as venous
thromboembolism and stroke (Collaborative Group on
Hormonal Factors in Breast Cancer, 1997; Million Women
Study Collaborators, 2003).
Observational studies suggest that Asian women who
consume diets typically high in isoflavones from soyabean
have a lower rate of postmenopausal fractures than Caucasian
women (Setchell and Lydeking-Olsen, 2003; Messina et al.,
2004; McCarty, 2006). Genistein aglycone is a non-glucoside
isoflavone found in low concentrations in soyabeans and in
elevated amounts in certain soyabean-derived foods, whereas
genistin, the glucoside form of the aglycone genistein, is
much more abundant in the unprocessed soyabean.
Genistein aglycone, acting similar to a SERM, might play a
preventive role against bone mass loss without the harmful
oestrogenic activity on reproductive tissues. Although its
mechanism of action on bone is not yet fully understood, it
is likely that the positive effects of this isoflavone are a direct
consequence of a greater binding affinity for the ER-b,
compared with that for ER-a, causing positive effects on bone
during the mineralization phase (Messina et al., 2004;
McCarty, 2006).
We have previously shown that treatment with pure
genistein aglycone increased bone mineral density (BMD) at
the lumbar spine and femoral neck in postmenopausal women
with no clinically significant adverse effects on the breast and
uterus (Morabito et al., 2002; Marini et al., 2007). In the same
cohort, genistein decreased the ratio of soluble receptor
activator of nuclear factor-kB ligand (sRANKL) to osteoprote-
gerin (OPG), which is well correlated with changes in BMD
(Crisafulli et al., 2004; Marini et al., 2008). These clinical data
suggest genistein aglycone as a possible safe therapeutic
alternative for the treatment of postmenopausal osteoporosis.
Albertazzi (2002) has suggested that genistein aglycone would
be a potentially useful, oral, bone anabolic agent.
In the light of these results, we investigated whether
genistein aglycone might be a useful alternative treatment
for postmenopausal osteoporosis compared with other
commonly used therapies such as alendronate, raloxifene
and oestradiol in an OVX animal model of established
osteoporosis. Bone quality comparisons were also performed
to assess each agent’s effect on bone structure.
Materials and methods
Animals
All procedures complied with the standards for care and use
of animal subjects as stated in the Guide for the Care and Use
of Laboratory Animals (Institute of Laboratory Animal
Resources, National Academy of Sciences, Bethesda, MD,
USA). The experimental protocols were reviewed and
approved by the Ethics Committee of the University of
Messina. A total of 108 OVX and 12 sham OVX female
Sprague–Dawley rats (Charles River, Calco, Italy), aged 12
weeks and weighing about 250–275g were purchased.
At 6 months following surgery, postmenopausal osteo-
porosis was assessed by BMD measurement and animals were
then randomized into different experimental groups. During
the experiment, animals were housed in the Animal Facility
of the Department of Clinical and Experimental Medicine
and Pharmacology of University of Messina, maintained
under controlled environmental conditions (12-h light–dark
cycle, temperature approximately 241C), and provided with
standard food for laboratory animals and water ad libitum.
Body weight was monitored throughout the study.
Randomization and treatments
At 6 months after ovariectomy (age: 9 months), animals were
divided into 9 groups of 12 animals each (Table 1). A group of
OVX rats was left untreated (untreated OVX). Both the
untreated OVX and the sham OVX groups were used as
controls. The different treatments (genistein aglycone (1 and
10mgkg
 1); alendronate (0.003 and 0.03mgkg
1); 17-a-ethinyl
oestradiol (0.003 and 0.03mgkg
 1); raloxifene hydrochloride
(0.05 and 0.5mgkg
 1)) were administered subcutaneously,
daily, for 12 weeks. All animals underwent BMD and bone
mineral content (BMC) evaluation at baseline and after 12
weeks of treatment. At the end of the experiment (animals
aged approximately 12 months), BMD and BMC were taken,
blood was collected for the subsequent analysis, right femurs
were removed for histology, fixed in 10% neutral-buffered
formalin and stored. Left femurs were disarticulated and
immediately tested for strength assessment.
Assays for BMD and BMC
BMD and the relative BMC of the femurs were measured
using dual-energy X-ray absorptiometry (Hologic QDR-4500A;
Hologic, Waltham, MA, USA). For basal and final measure-
ments, animals were anaesthetized with sodium pentobarbital
(50mgkg
 1 i.p.). During the analysis period, daily measure-
ments were made for BMD and BMC following the manu-
facturer’s instructions, to assess the long-term reproducibility
of the measured parameters quality control (QC). A measured
value of ±1.5% was taken as acceptable. Whenever two points
obtained in succession were found outside the limits of the QC
curve, the procedure was repeated. The coefficient of variation
for femur BMD and BMC was 1.15 and 1.10%, respectively.
Moreover, accuracy of BMD and BMC final measurements
were determined by duplicate scans of femurs.
Body weight, biochemical analysis and uterine assessments
Body weight (expressed in grams) was monitored at the end
of the experiments. After blood collection by cardiac
puncture under general anaesthesia (sodium pentobarbital
50mgkg
 1 i.p.), animals were killed. Uteri were removed
immediately after perfusion fixation and weights were
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stored immediately at  201C for analysis.
Sera were then collected to evaluate in duplicate, by
commercially available ELISA kits, calcium, phosphorus
(Wako Pure Chemical Industries Ltd, Wako, Bethesda, MD,
USA), bone-alkaline phosphatase (b-ALP; IDS Ltd, UK),
collagen C-telopeptide (CTX, Nordic Bioscience Diagnostics,
Nordic, Herlev, Denmark), OPG (IDS Ltd) and soluble
receptor activator of NF-kB ligand (sRANKL; IDS Ltd).
Femur-breaking strength
Immediately after death, the maximum load (breaking
strength) tolerated by femurs was measured without knowl-
edge of the treatments, on coded samples using a calibrated
tensometer (Sans, Shenzen, China). A three-point bending
strength test was performed, femurs were placed horizontally
on a two-point sample holder (15mm span) with the anterior
aspect facing up, and a load was placed at the centre of the
bone at the rate of 10.0mm/min until the bone fractured.
Maximum tolerated load was expressed in Newton (N).
Histology
Analysis was performed by an investigator, unaware of the
treatments. For tissue collection, the leg was disarticulated at
the hip, knee and ankle. For microscopic histological
evaluation, femurs were removed and immediately fixed in
10% neutral-buffered formalin.
The femur was cleaned of soft tissue, placed in decalcifying
solution (8% hydrochloric acid (37% v/v) and 10% formic
acid (89% v/v) in phosphate-buffered saline) for about 24h
at 371C, dehydrated in 95% (v/v) ethanol and then
embedded in paraffin. Three 5-mm-thick paraffin-embedded
horizontal bone sections were cut from the proximal end of
the diaphysis, stained with haematoxylin–eosin and exam-
ined by light microscopy. Femur heads (the area between the
hip joint cartilage and metaphyseal cartilage) were assessed
for the quality of bone and trabecular density, according to
the score shown in Table 2. Cartilage integrity is considered
as an additional index of bone quality, because osteoporosis
is also responsible for cartilage deterioration and treatments
that restore bone integrity are also able to preserve a good
trophism of the cartilage indirectly.
Statistical analysis
All data are expressed as means±s.d. The significance of
difference in BMD femoral neck and BMC was assessed by
a two-way repeated measures ANOVA followed by Tukey’s
Table 2 Criteria for the evaluation of the histological score used to assess the degree of osteoporosis
Score Hip joint cartilage integrity Structure of trabecular bone Quantity of trabecular bone (% of interest area)
0 Cartilage complete Normal 90–100
1 Cartilage complete Partially reduced 60–90
2 Cartilage partially complete Markedly reduced 30–60
3 Cartilage absent Absent 0–30
Table 1 Flow chart of experimental protocol
Intact female rats
 3 months
Start of the 
experiment
 6 months
Ovx rats 
Age: 3 months
Ovariectomy
Ovx rats
Age: 9 months
Development of 
osteoporosis
 3 months
Ovx rats
Age: 12 months
End of the 
experiment
Assessment of basal BMD 
and BMC and randomization
to the treatment
Assessment of final BMD and
BMC, evaluation of breaking
strength and other outcome
measures 
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between different treatments were analysed by one-way
ANOVA followed by Tukey’s multiple comparison test. In all
cases, a probability error of less than 0.05 was selected as the
criterion for statistical significance. Graphs were drawn using
GraphPad Prism (version 4.0 for Windows).
Drugs
Genistein aglycone was a kind gift of Primus Pharmaceuticals
Inc., Scottsdale, AZ, USA; alendronate, 17-a-ethinyl oestra-
diol and raloxifene hydrochloride were purchased from
Sigma Aldrich (Milan, Italy). All substances were prepared
fresh daily and administered at a volume of 100mL. The
vehicle used to solubilize genistein aglycone, raloxifene and
oestradiol was 33% DMSO in 0.9% NaCl, whereas alendro-
nate was dissolved in a 0.9% NaCl solution.
Results
Effect of the different treatments on body weight, uterine weight,
and serum calcium and phosphorus
The final body weights were significantly greater for animals
in the OVX treatment and untreated groups (Table 3)
compared with the sham OVX animals. There were no
statistically significant differences in weights observed
between any of the active treatment groups and that of the
untreated OVX control group (Table 3).
The final serum calcium and phosphorus levels were
not significantly different between the sham OVX and the
OVX animals. Likewise, there were no changes in the blood
levels of these two elements observed among the several
pharmacological treatments (Table 3).
The final uterine weights were decreased in the OVX
untreated control group compared with sham OVX rats. The
OVX rats treated with 17-a-ethinyl oestradiol had signifi-
cantly greater uterine weights compared with both untreated
OVX and the treatment groups (Table 3).
Effect of the treatments on femoral BMD and BMC
At 6 months after ovariectomy, OVX animals had a
significant decrease in femoral neck BMD compared with
sham OVX animals (Po0.0001; Figure 1a) as well as in BMC
(Po0.0001; Figure 1b). After 12 weeks of therapy, all the
active treatments succeeded in increasing BMD and BMC in
OVX animals. Both doses of genistein aglycone produced
marked increases in BMD (Po0.0001 vs OVX) and BMC
(Po0.0001 vs OVX) as shown in Figures 1a and b. Compar-
ing results for each therapy, the higher dose of genistein
aglycone showed a greater increase in both BMD and BMC
than all the other treatments (Figures 1a and b). Alendro-
nate, the most effective drug for postmenopausal osteoporo-
sis, showed a statistically significant lower bone-building
capability compared with genistein aglycone in this model
(Po0.0001).
Effect of the treatments on bone markers
At the end of experiment, serum levels of b-ALP, a marker of
bone formation, were significantly higher (Figure 2a) in the
untreated OVX group than in the sham OVX group
(Po0.0001). Genistein aglycone also significantly increased
the b-ALP (Po0.0001 vs OVX) over all other treatments.
None of the other therapeutic interventions significantly
affected b-ALP at any dose level (Figure 2a).
The serum levels of the bone resorption marker CTX were
significantly higher in the OVX untreated group than in the
sham OVX group (Po0.0001). Alendronate, raloxifene
hydrochloride and 17-a-ethinyl oestradiol significantly
reduced CTX plasma levels at any dose levels (Figure 2b).
Genistein aglycone administration also reduced the circulat-
ing levels of the resorption marker: indeed the higher dose of
the isoflavone caused a greater decrease in CTX than the
other treatments at any dose levels (Po0.0001 vs OVX).
At the end of experiment, serum levels of sRANKL were
significantly higher, whereas serum OPG levels were lower in
the OVX untreated group than in the sham OVX group
(Po0.0001) (Figures 3a and b). As a consequence, the
sRANKL/OPG ratio was higher in OVX rats than in sham
OVX animals (Po0.001; Figure 3c). All the pharmacological
interventions significantly increased OPG concentration,
reduced sRANKL and lowered the sRANKL/OPG ratio in
OVX rats. However, the effect of genistein aglycone
(10mgkg
 1) on the OPG system was greater than the other
treatment at any dose tested (sRANKL/OPG: Po0.001 vs
OVX) (Figures 3a–c).
Table 3 Effects of alendronate, raloxifene, genistein and oestradiol on body weight, uterine weight, calcium and phosphorus serum levels
Treatment Body weight (g) Uterine weight (g) Calcium (mgmL
-1) Phosphorus (mgmL
 1)
Sham OVX 260±18 0.63±0.06* 102.2±2.7 86.4±1.8
OVX untreated 355±12 0.38±0.05 100±3 84.7±1.7
OVXþalendronate (0.003mgkg
 1)3 5 2 ±10 0.37±0.05 97.7±2.1 86.1±1.3
OVXþalendronate (0.03mgkg
 1)3 5 3 ±8 0.38±0.04 99.1±1.2 85.8±1.5
OVXþ17-a-ethinyl oestradiol (0.003mgkg
 1)3 5 0 ±13 0.51±0.06* 98±1.3 85.3±1.9
OVXþ17-a-ethinyl oestradiol (0.03mgkg
 1)3 5 2 ±10 0.48±0.05* 97.5±1.2 84.5±1.2
OVXþgenistein (1mgkg
 1)3 5 0 ±14 0.38±0.06 100.3±2.1 85.3±2
OVXþgenistein (10mgkg
 1)3 4 2 ±12 0.38±0.03 100.7±2.5 86±2.1
OVXþraloxifene hydrochloride (0.05mgkg
 1)3 5 3 ±9 0.37±0.04 99.8±2.4 84.3±2
OVXþraloxifene hydrochloride (0.5mgkg
 1)3 5 5 ±11 0.38±0.05 99.6±3.1 84.9±1.4
Abbreviation: OVX, ovariectomized.
*Po0.05 vs corresponding value in OVX-untreated group; n¼12 for all groups.
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and on bone quality
In the results obtained from the three-point bending test of
the femur, untreated OVX animals had significantly
reduced breaking strength compared with sham OVX rats
(Po0.0001) (Figure 4a). All the pharmacological treatments
succeeded in improving the breaking strength of the femur.
Genistein aglycone, however, caused a greater increase in the
amount of pressure required to fracture the femur compared
with other treatments at any dose level tested (Po0.0001;
Figure 4a).
The histological score (Figure 4b) of all groups evaluated
following the criteria shown in Table 1 revealed a greater
effect of genistein aglycone on bone quality compared with
all the other treatments at any dose level tested. Bone
histology (Figures 5 and 6) revealed a marked effect of
genistein aglycone in treating osteoporosis induced by
ovariectomy. Histology of the femur head in animals treated
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Figure 2 Effects of alendronate, raloxifene, genistein and oestradiol on serum bone-alkaline phosphatase (b-ALP) (a) and collagen
C-telopeptide (CTX) (b) in ovariectomized (OVX) rats. Data are shown as the mean±s.d. of 12 animals. b-ALP: *Po0.0001 vs untreated OVX;
#P¼0.098 vs untreated OVX;
yP¼ 0.005 vs untreated OVX; 1Po0.0001 vs untreated OVX. CTX: *Po0.0001 vs untreated OVX;
#P¼0.008 vs
untreated OVX; 1Po0.0001 vs untreated OVX.
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Figure 1 Effects of alendronate, raloxifene, genistein and oestradiol on femoral bone mineral density (BMD) (a) and bone mineral content
(BMC) (b) in ovariectomized (OVX) rats. Data are shown as the mean±s.d. of 12 animals. BMD: *Po0.0001 vs untreated OVX;
#Po0.005 vs
untreated OVX;
yPo0.0001 vs untreated OVX; 1Po0.0001 vs all other treatments. BMC: *Po0.0001 vs untreated OVX;
#P¼0.006 vs
untreated OVX,
yPo0.0001 vs untreated OVX.
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cortical and trabecular bone with well-organized bone
matrix correlating with the enhanced resistance to fracture
(Figure 4a), observed in femurs subjected to a constant load
(Po0.0001 vs OVX).
Discussion
This study clearly shows that genistein aglycone, a well-
known, but low concentration, soyabean isoflavone, was
able to counteract the bone loss in an experimental model of
established osteoporosis. In this context, the OVX rat is
considered an appropriate model for studying human
menopausal osteoporosis because of many similarities in
their pathophysiological mechanisms of bone deterioration
(Kalu, 1991; Wronski et al., 1991; Frost and Jee, 1992).
Drugs that interfere with steps in the resorptive pathway
resulting in bone loss (antiresorptive agents) (Jordan et al.,
2006) or that amplify or mimic steps in the anabolic
pathway to build new and improved skeletons (anabolic or
bone-forming agents) are specifically recommended to
treat bone loss (Canalis et al., 2007). Safe anabolic agents
are needed to build bone, restoring both bone structure
and strength, rather than just prevention or slower progres-
sion of bone fragility, as occurs with current antiresorptive
agents.
Oestrogen replacement therapy, SERMs (that is, raloxifene
hydrochloride) and bisphosphonates (that is, alendronate)
are widely used to oppose accelerated bone resorption in
senile or postmenopausal osteopaenia/osteoporosis. All of
these treatments predominantly exert antiresorptive effects
by inhibiting, through several different mechanisms, the
activity of osteoclasts (Jordan et al., 2006) rather than
promoting osteoblast activity. Increasing clinical evidence
suggests a role for genistein aglycone in the treatment
of postmenopausal bone loss (Morabito et al., 2002;
Marini et al., 2007, 2008); however, proof of efficacy in the
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Figure 3 Effects of alendronate, raloxifene, genistein and oestradiol on serum osteoprotegerin (OPG) (a), soluble receptor activator of NF-kB
ligand (sRANKL) (b) and sRANKL/OPG (c) in ovariectomized (OVX) rats. Data are shown as the mean±s.d. of 12 animals. OPG: *Po0.0001 vs
untreated OVX; 1Po0.0001 vs all other treatments;
#Po0.0001 vs untreated OVX. sRANKL: *Po0.0001 vs untreated OVX;
#P¼0.002 vs
untreated OVX;
yP¼0.003 vs untreated OVX; 1Po0.0001 vs all other treatments;
$Po0.0001 vs untreated OVX. sRANKL/OPG: *Po0.0001 vs
untreated OVX;
#P¼0.002 vs untreated OVX;
yP¼0.003 vs untreated OVX; 1Po0.0001 vs all other treatments;
$Po0.0001 vs untreated OVX.
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et al., 2007).
Our experimental data demonstrate that two doses of
genistein aglycone, given by subcutaneous injection in OVX
osteoporotic rats, were able to produce a marked increase in
BMD and BMC in accordance with our recent observations in
osteopaenic, postmenopausal women treated orally (the
preferable route of administration), with 54mg per day of
aglycone genistein (Morabito et al., 2002; Marini et al., 2007,
2008), in the same range of dosing, as that used in
the present experimental model. Not only did genistein
aglycone increase BMD and BMC but the isoflavone
also restored structure to osteoporotic bone as well or
better than other well-accepted treatments. Indeed, some
of the positive effects of genistein aglycone that we observed
have been previously reported (Fanti et al., 1998; Ishimi
et al., 2000) in both young OVX rats and mice, treated
subcutaneously.
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Figure 4 Effects of alendronate, raloxifene, genistein and oestradiol on femur-breaking strength (a) and histological score (b)i n
ovariectomized (OVX) rats. Data are shown as the mean±s.d. of 12 animals. Femoral-breaking strength: *Po0.0001 vs untreated OVX;
#P¼0.006 vs untreated OVX; 1Po0.0001 vs untreated OVX. Histological score: *Po0.0001 vs untreated OVX; 1Po0.05 vs all other treatments.
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Figure 5 (a–f) Light microscopy of the cortical and trabecular structure of the femur head: effects of alendronate and raloxifene
(haemotoxylin and eosin, original magnification  5).
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genistein aglycone was more effective than alendronate, a
very useful drug for the prevention of fractures in post-
menopausal women with osteoporosis (Iwamoto et al.,
2007), in inhibiting osteoclastic markers, CTX and sRANKL.
In addition, genistein aglycone, at any dose tested, signifi-
cantly reduced CTX and sRANKL plasma levels to a greater
extent than raloxifene hydrochloride or 17-a-ethinyl oestra-
diol. Genistein aglycone was also the most effective treat-
ment in terms of the osteoblastic activity markers, b-ALP,
OPG and had a better sRANKL/OPG ratio. These findings
show the positive and unique role of genistein aglycone in
stimulating osteoblasts, while also damping osteoclasts,
compared with all the other available current therapies for
osteoporosis. However, the basis of the ‘dual’ activity is
unknown.
Unlike 17b-oestradiol, which displays relatively equivalent
binding on both ER subtypes, and raloxifene, which binds
with greater affinity to ER-a, genistein aglycone binds
selectively to ER-b over ER-a, from 7- to 48-fold, depending
on the assay system employed (Kuiper et al., 1997, 1998;
Barkhem et al., 1998; Hsieh et al., 2006). Despite a relatively
low affinity for ER-a, genistein aglycone can act as a full
agonist in some assay systems (Barkhem et al., 1998). The
selective activation of ER-b by genistein aglycone is likely to
be mediated by a greater capacity to recruit co-regulators of
ER-b, than those of ER-a (An et al., 2001), through de novo
protein synthesis in osteoblasts (Yamaguchi and Sugimoto,
2000; Yamaguchi et al., 2000). Osteoblasts express both
receptor types and can be influenced by selective binding of
oestrogenic compounds (Onoe et al., 1997; Valachovicova
et al., 2004). The consequence of selective receptor modula-
tion is enhanced transcriptional activation or repression of
promoters and other genes under ER-b regulation, relative to
those regulated by ER-a.
ER-b is robustly expressed in developing human bone,
especially the trabecular bone that is most subject to loss
following gonadal hormone deprivation (Bord et al., 2001).
There is a greater than ninefold increase in ER-b expression
in cultured human osteoblasts during bone mineralization,
whereas ER-a levels remain unchanged during this process
(Arts et al., 1997; Setchell and Lydeking-Olsen, 2003).
Though experimental observations support the role for
positive actions of genistein aglycone on bone that could
OVX Genistein 10 mg kg-1
OVX Oestradiol 0.03 mg kg-1 OVX Oestradiol 0.003 mg kg-1
OVX Genistein 1 mg kg-1
Figure 6 (a–d) Light microscopy of the cortical and trabecular structure of the femur head: effects of genistein and oestradiol (haemotoxylin
and eosin stain, original magnification  5).
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ER-a (Hertrampf et al., 2007), the accumulating evidence
strongly suggests the important involvement of ER-b in bone
formation and, by extension, the use of selective ER-b
agonists such as genistein aglycone to treat bone loss
through osteoblast stimulation. The increased b-ALP activity
of genistein aglycone in comparison to other treatments in
the current study is supportive of this mechanism of action.
The concentration of genistein aglycone must be properly
titrated, however, as some reports suggest insufficient
stimulation of ER-b may occur, leading to few or even absent
beneficial effects at low doses (Ma ¨kela ¨ et al., 1999; Setchell,
2001; Kostelac et al., 2003; Altavilla et al., 2004; McCarty,
2006).
Postmenopausal osteoporosis also results from an imbal-
ance between resorption and formation associated with
decreased OPG/RANKL balance (Simonet et al., 1997;
Hofbauer and Heufelder, 2000; Li et al., 2000), thus
indicating that the OPG/RANKL system might represent a
good pharmacological target in the treatment of osteoporo-
sis. Genistein aglycone has been shown to selectively
antagonize the bone catabolic effects of parathyroid hor-
mone in osteoblasts by reducing parathyroid hormone-
induced increases in RANKL and reversing decreases in
OPG expression in vitro (Chen and Wong, 2006). In the
present paper, all the pharmacological interventions signifi-
cantly increased OPG concentration, reduced sRANKL and
lowered sRANKL/OPG balance in OVX rats. However, the
effect of highest dose of genistein aglycone on the OPG
system was greater than the other treatment at any dose
tested. These data are in agreement with previous studies
indicating a strong effect of genistein aglycone on the OPG/
RANKL balance (Crisafulli et al., 2004; Marini et al., 2008),
highly correlated with the augmented BMD in femur neck
and lumbar spine.
Studies have also shown that genistein aglycone inhibits
tyrosine phosphorylation in osteoclasts at the same concen-
trations that reduce osteoclast number in vitro, presumably
by inducing osteoclast apoptosis (Gao and Yamaguchi,
2000). Increases in intracellular calcium signalling may also
in part mediate genistein aglycone’s inhibitory effects on
osteoclasts, as inhibitors of the calcium-dependent signalling
molecules, calmodulin and protein kinase C, antagonize the
reduction in osteoclast number induced by genistein
aglycone (Gao and Yamaguchi, 1999). Increases in osteoclast
intracellular calcium levels induced by genistein aglycone
may be mediated by direct inhibition of inward-rectifier K
þ
channels independent of genistein aglycone’s activity on
tyrosine kinases (Okamoto et al., 2001).
In conclusion, genistein aglycone showed a positive effect
on osteoporotic bone in the present experimental model
confirmed by decreasing osteoclastic resorption and increas-
ing osteoblastic formation markers. This putative ‘uncou-
pling’ of the bone remodelling process in bone growth may
be a selective event in osteoporotic bone. Though all
pharmacological treatments succeeded in improving the
breaking strength of the femur, genistein aglycone caused
the greatest increase in breaking strength and was supported
by restored bone architecture in the femoral head of OVX-
treated rats. Collectively, our results strongly suggest that
genistein aglycone might be a new potential therapy for the
management of postmenopausal osteoporosis in humans
combining a powerful bone-forming as well as an anti-
resorptive activity.
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